Digital Transformation

Five Months to Three Weeks: What Integrated Digital Infrastructure Actually Delivers

by | Jul 8, 2026 | , , , ,

A conversation between Bill Burke, CEO of Merit Solutions, and Matt Birtwistle of Nexer A clinical-stage therapy sponsor arrives at your facility with data, regulatory clearance, and a need for GMP-grade DNA plasmid material. They need to know when you can deliver it. Your answer is five months. That was the reality facing one of Merit Solutions' CDMO customers before they invested in integrated digital infrastructure. Bill Burke, CEO of Merit Solutions, shared the story in a recent conversation with Matt Birtwistle of Nexer. The stakes extended well beyond a scheduling problem. Hundreds of DNA-based therapies are in active development, nearly all of them targeting critical patient populations where time to clinic is measured in lives, not quarters. A five-month order cycle was a...

read more

Biopharma and Medtech Funding Is Back – But the Rules Have Changed

by | Apr 7, 2026 | , , , , , ,

What the Return of Capital Means for Life Science Manufacturers For the past three-plus years, many of the most innovative companies in biopharmaceutical and medical technology have been doing something remarkable: advancing life-changing science on a shoestring. Capital was scarce, investors were cautious, and the road to getting a drug or therapy to market felt longer and lonelier than ever. That's changing. According to a Wall Street Journal report from January, publicly traded drug and life science companies raised more than $13 billion from new stock issuances in the fourth quarter of 2025 - the highest level in more than four years. Investor confidence in the sector is measurably returning.1 As someone who has spent more than 20 years working alongside biopharmaceutical and medical...

read more

Why true Cloud ERPs beat traditional ERP for Biopharma Compliance

by | Feb 19, 2026 | ,

Private cloud ERP might feel safer, but SaaS ERP offers a better compliance model for biopharma by reducing validation overhead, cutting costs, and enabling continuous compliance and innovation. SaaS ERP vs Private Cloud: A Better Compliance Model for Biopharma Life sciences companies use enterprise resource planning (ERP) systems to manage complex business processes and optimize operations for growth and efficiency. Governed by stringent regulations, life science manufacturers must maintain tight control over the entire manufacturing process from raw materials through distribution to ensure quality control across the product lifecycle. They must also be able to track product...

read more

AI in Regulated Manufacturing: Beyond the Hype to Real-World Implementation 

by | Feb 10, 2026 | , , , , , , , ,

The artificial intelligence conversation has reached a fever pitch across industries, and life science manufacturing is no exception. For GMP-regulated manufacturers operating under FDA, EMA, and MHRA oversight, however, the path to AI adoption looks fundamentally different than what you're reading about in mainstream tech headlines.  The work ahead is clear: helping our customers leverage this new capability in ways that improve product quality, enhance customer experience, and drive operational efficiency across their organizations.  The Reality Check: Not All AI Models Are Created Equal  The ability to leverage AI will likely prove more impactful than even most people realize. The capability to transform...

read more

Lessons from 483 Inspections: CFR 21 Part 211

by | Mar 15, 2024 | , , , , , ,

In the highly regulated world of drug and biotechnology manufacturing, adhering to FDA regulations is essential not just legally, but also for protecting patient health, ensuring quality and building market trust. This blog highlights a critical trend: over 50% of the compliance issues noted during FDA Inspections (as documented in 483 Letters) for drug manufacturers (including some biotechnology firms) have focused on specific sections of FDA CFR 21 Part 211. This indicates a crucial area for compliance improvement to maintain operational integrity and uphold industry standards.  Understanding CFR 21 Part 211 and Recent Observations:  FDA CFR 21 part 211 outlines the regulations for the manufacturing, processing, packing, or holding of drug...

read more

Lessons from 483 Inspections: Navigating FDA Compliance for Drug and Biotech Manufacturers

by | Mar 14, 2024 | , , , , ,

In the biopharmaceutical industry, ensuring public health and product safety is paramount. Regular inspections by the Food and Drug Administration (FDA) are crucial to this mission. Even for established companies, the prospect of receiving a Form 483 (a document outlining potential compliance issues) following an inspection can be nerve-wracking.  Common Areas of Non-Compliance The FDA's Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER) publish annual data on the number of 483s issued and aggregated data on the particular types of issues cited in the 483 letters. While each individual 483 letter is unique, looking at the data in aggregate reveals recurring themes, such as:  Quality systems: Deficiencies in quality...

read more